Exicure

Exicure, formerly known as AuraSense Therapeutics, is pioneering a new class of immunomodulatory and gene silencing drugs targeting validated medical conditions. Utilizing a 3-dimensional, spherical nucleic acid (SNA™) structure, the company enhances the efficacy of nucleic acid therapeutics across various organs. Its primary programs focus on a range of diseases from inflammatory disorders to oncology. SNA constructs address one of the most challenging hurdles in nucleic acid therapeutics: achieving safe and effective delivery into cells and tissues. These constructs demonstrate exceptional transfection efficiency across numerous cell and tissue types, including the skin, without the need for carriers or transfection agents. Additionally, SNAs serve as powerful immunotherapeutic agents for treating cancer and infectious diseases. Founded in 2009, Exicure operates in the Biotechnology industry. The company recently secured a $5.40M Post-IPO Equity investment from CBI USA on 26 September 2022.